ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 78 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,868,923 | -34.8% | 389,359 | +2.1% | 0.00% | – |
| Q2 2023 | $2,864,457 | +60.9% | 381,419 | -3.2% | 0.00% | – |
| Q1 2023 | $1,780,627 | -79.9% | 393,944 | -49.9% | 0.00% | – |
| Q4 2022 | $8,870,618 | +141.0% | 787,100 | +104.7% | 0.00% | – |
| Q3 2022 | $3,680,000 | +27.9% | 384,563 | +8.1% | 0.00% | – |
| Q2 2022 | $2,878,000 | -92.0% | 355,805 | -83.3% | 0.00% | -100.0% |
| Q1 2022 | $36,060,000 | +16.3% | 2,133,744 | +47.9% | 0.00% | +100.0% |
| Q4 2021 | $30,996,000 | -51.3% | 1,442,334 | +67.4% | 0.00% | -66.7% |
| Q3 2021 | $63,634,000 | +10.3% | 861,555 | -18.3% | 0.00% | 0.0% |
| Q2 2021 | $57,681,000 | -15.7% | 1,054,877 | +13.7% | 0.00% | -25.0% |
| Q1 2021 | $68,389,000 | +107.4% | 927,439 | +142.4% | 0.00% | +100.0% |
| Q4 2020 | $32,975,000 | +669.7% | 382,539 | +237.0% | 0.00% | – |
| Q3 2020 | $4,284,000 | – | 113,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |